Stock comparison
IDEXX Laboratories
Xeris Biopharma Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
XERS
Xeris Biopharma Holdings
Market cap
$1.13B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | XERS | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 49D | IDXX |
| Benjamin Graham | 72B | 75B | XERS |
| Philip Fisher | 67B | 64C | IDXX |
| Peter Lynch | 63C | 80A | XERS |
| Joel Greenblatt | 75B | 48D | IDXX |
| Charlie Munger | 79B | 58C | IDXX |
| Terry Smith | 76B | 59C | IDXX |
Side-by-side metrics
| Metric | IDXX | XERS |
|---|---|---|
| Market cap | $42.11B | $1.13B |
| P/E (TTM) | 39.0x | 92.7x |
| EV/EBIT | 31.6x | 42.3x |
| ROIC (TTM) | 40.66% | 12.84% |
| Gross margin | 62.05% | 81.59% |
| Net margin | 24.63% | 3.81% |
| Revenue CAGR 5y | 7.56% | 55.75% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 2.9x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$42.11Bvs $1.13B+97%
- Net margin24.63%vs 3.81%+85%
- Debt / Equity0.7xvs 2.9x+76%
- ROIC (TTM)40.66%vs 12.84%+68%
XERS leads on
- Revenue CAGR 5y55.75%vs 7.56%+86%
- Gross margin81.59%vs 62.05%+24%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.